Hydrocortisonbutyrate 0,1 % cutanenous use (class II)

Generic name
Hydrocortisonbutyrate 0,1 % cutanenous use (class II)
Brand name
ATC Code
D07AB02
Compare …

Hydrocortisonbutyrate 0,1 % cutanenous use (class II)

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

PK data not reviewed

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Atopic dermatitis
  • Cutaneous
    • 1 month up to 18 years
      [1] [4]
        • Apply to the affected skin once daily according to finger-tip-unit method <insert link to FTU page).
        • Maximum dose: < 2 yrs: 30 g/week; ≥ 2 years: 60 grams/week; adults: no restriction.
        • With improvement, taper to 1once daily dosing for 2-4 days/week.

        Note the difference between hydrocortisone acetate (class I) and hydrocortisone butyrate (class II).

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Prolonged use and use of high doses- especially when the skin is covered with, for example, a diaper -may lead to systemic side effects. (SmPC)

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

In infants, the diaper may act as an occlusive dressing, thereby increasing systemic absorption and leading to systemic effects. Children have a relatively large skin surface area and thin skin. Prolonged use of dermatocorticosteroids on large and damaged skin surfaces can potentially lead to more rapid systemic side effects, adrenal suppression and also growth hormone suppression in them. It is therefore recommended, when long-term application is necessary, that height and weight be monitored regularly.

When applying to the eyelids, careful consideration should be given to the possibility of contamination of the conjunctiva with the risk of developing glaucoma simplex or sub-capsular cataract on the one hand and the risk of corneal damage due to continuous rubbing of untreated exudate on the other hand.

 

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

CORTICOSTEROIDS, PLAIN

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Corticosteroids, weak (group I)
D07AA02
Corticosteroids, potent (group III)
D07AC01
D07AC03
D07AC17
D07AC13

References

  1. Nederlandse Vereniging voor Dermatologie en Venerelogie, Richtlijn constitutioneel eczeem., 2019
  2. Nederlandse Vereniging voor Dermatologie en Venerelogie, Leidraad Dermatocorticosteroiden, 2019
  3. ZorgInstituut Nederland, Farmacotherapeutisch kompas (Eigenschappen, bijwerkingen, contra-indicaties, waarschuwingen en voorzorgen), Geraadpleegd 28 jun 2021
  4. CHEPLAPHARM Arzneimittel GmbH, SmPC Alfason® 0,1 % Creme (4932.00.00)/Salbe/Cresa/Crinale/Crelo, 03/2021

Changes

Therapeutic Drug Monitoring


Overdose